Cipla Subsidiary's USFDA Inspection Classified as VAI

Cipla Ltd announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., received communication from the USFDA regarding an inspection conducted at its Unit 3 manufacturing facility in Long Island, New York. The inspection, which took place from July 13-17, 2026, has been classified by the USFDA as Voluntary Action Indicated (VAI). This classification suggests that while the inspection identified some issues, they do not currently warrant mandatory regulatory action, indicating a positive outcome for the facility's compliance status.